Positive predictive values and outcomes for uninformative cell-free DNA tests: An Italian multicentric Cytogenetic and cytogenomic Audit of diagnOstic testing (ICARO study).
Journal
Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
10
11
2022
received:
05
08
2022
accepted:
11
11
2022
pubmed:
21
11
2022
medline:
16
12
2022
entrez:
20
11
2022
Statut:
ppublish
Résumé
To establish the positive predictive values (PPV) of cfDNA testing based on data from a nationwide survey of independent clinical cytogenetics laboratories. Prenatal diagnostic test results obtained by Italian laboratories between 2013 and March 2020 were compiled for women with positive non-invasive prenatal tests (NIPT), without an NIPT result, and cases where there was sex discordancy between the NIPT and ultrasound. PPV and other summary data were reviewed. Diagnostic test results were collected for 1327 women with a positive NIPT. The highest PPVs were for Trisomy (T) 21 (624/671, 93%) and XYY (26/27, 96.3%), while rare autosomal trisomies (9/47, 19.1%) and recurrent microdeletions (8/55, 14.5%) had the lowest PPVs. PPVs for T21, T18, and T13 were significantly higher when diagnostic confirmation was carried out on chorionic villi (97.5%) compared to amniotic fluid (89.5%) (p < 0.001). In 19/139 (13.9%), of no result cases, a cytogenetic abnormality was detected. Follow-up genetic testing provided explanations for 3/6 cases with a fetal sex discordancy between NIPT and ultrasound. NIPT PPVs differ across the conditions screened and the tissues studied in diagnostic testing. This variability, issues associated with fetal sex discordancy, and no results, illustrate the importance of pre- and post-test counselling.
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1575-1586Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Gadsbøll K, Petersen OB, Gatinois V, et al. Current use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation. Acta Obstet Gynecol Scand. 2020;99(6):722-730. https://doi.org/10.1111/aogs.13841
Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA. 2008;105(42):16266-16271. https://doi.org/10.1073/pnas.0808319105
Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA. 2008;105(51):20458-20463. https://doi.org/10.1073/pnas.0810641105
Ryan A, Hunkapiller N, Banjevic M, et al. Validation of an enhanced version of a single-nucleotide polymorphism-based noninvasive prenatal test for detection of fetal aneuploidies. Fetal Diagn Ther. 2016;40(3):219-223. https://doi.org/10.1159/000442931
Ericsson O, Ahola T, Dahl F, et al. Clinical validation of a novel automated cell-free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma. Prenat Diagn. 2019;39(11):1011-1015. https://doi.org/10.1002/pd.5528
Stokowski R, Wang E, White K, et al. Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies. Prenat Diagn. 2015;35(12):1243-1246. https://doi.org/10.1002/pd.4686
Peng XL, Jiang P. Bioinformatics approaches for fetal DNA fraction estimation in noninvasive prenatal testing. Int J Mol Sci. 2017;18(2):453. https://doi.org/10.3390/ijms18020453
Bianchi DW, Chiu RWK. Sequencing of circulating cell-free DNA during pregnancy. N Engl J Med. 2018;379(5):464-473. https://doi.org/10.1056/nejmra1705345
Jones R, White K, Batey A, Kostenko E. Cell-free DNA testing for prenatal aneuploidy assessment: analysis of professional society statements. Ultrasound Obstet Gynecol. 2021;57(5):840-841. https://doi.org/10.1002/uog.22120
Petersen AK, Cheung SW, Smith JL, et al. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory. Am J Obstet Gynecol. 2017;217(6):691.e1-691.e6. https://doi.org/10.1016/j.ajog.2017.10.005
Meck JM, Kramer Dugan E, Matyakhina L, et al. Noninvasive prenatal screening for aneuploidy: positive predictive values based on cytogenetic findings. Am J Obstet Gynecol. 2015;213(2):214.e1-e5. https://doi.org/10.1016/j.ajog.2015.04.001
Reiss RE, Discenza M, Foster J, Dobson L, Wilkins-Haug L. Sex chromosome aneuploidy detection by noninvasive prenatal testing: helpful or hazardous? Prenat Diagn. 2017;37(5):515-520. https://doi.org/10.1002/pd.5039
Gardner MRJ, Amor DJ. Chromosome abnormalities detected at prenatal diagnosis. In: Gardner and Sutherland's Chromosome Abnormalities and Genetic Counseling. 5th ed. Oxford University Press monographs on medical genetics; 2018:p466-p515.
Bianchi DW, Parsa S, Bhatt S, et al. Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet Gynecol. 2015;125(2):375-382. https://doi.org/10.1097/aog.0000000000000637
Lüthgens K, Grati FR, Sinzel M, Habig K, Kagan KO. Confirmation rate of cell free DNA screening for sex chromosomal abnormalities according to the method of confirmatory testing. Prenat Diagn. 2021;41(10):1258-1263. https://doi.org/10.1002/pd.5814
Dar P, Curnow KJ, Gross SJ, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol. 2014;211(5):527.e1-527.e17. https://doi.org/10.1016/j.ajog.2014.08.006
Liang D, Cram DS, Tan H, et al. Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromes. Genet Med. 2019;21(9):1998-2006. https://doi.org/10.1038/s41436-019-0467-4
Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW, Burton GJ. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol. 2006;169(2):400-404. https://doi.org/10.2353/ajpath.2006.060161
Flori E, Doray B, Gautier E, et al. Circulating cell-free fetal DNA in maternal serum appears to originate from cyto- and syncytio-trophoblastic cells. Case report. Hum Reprod. 2004;19(3):723-724. https://doi.org/10.1093/humrep/deh117
Faas BH, de Ligt J, Janssen I, et al. Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expet Opin Biol Ther. 2012;12(suppl 1):S19-S26. https://doi.org/10.1517/14712598.2012.670632
Bianchi DW, Wilkins-Haug LE, Enders AC, Hay ED. Origin of extraembryonic mesoderm in experimental animals: relevance to chorionic mosaicism in humans. Am J Med Genet. 1993;46(5):542-550. https://doi.org/10.1002/ajmg.1320460517
Grati FR, Malvestiti F, Ferreira JC, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med. 2014;16(8):620-624. https://doi.org/10.1038/gim.2014.3
Grati FR, Bajaj K, Malvestiti F, et al. The type of feto-placental aneuploidy detected by cfDNA testing may influence the choice of confirmatory diagnostic procedure. Prenat Diagn. 2015;35(10):994-998. https://doi.org/10.1002/pd.4659
Grati FR, Malvestiti F, Gallazzi G, et al. Performance of conventional cytogenetic analysis on chorionic villi when only one cell layer, cytotrophoblast or mesenchyme alone, is analyzed. Prenat Diagn. 2021;41(6):652-660. https://doi.org/10.1002/pd.5941
Mardy AH, Norton ME. Diagnostic testing after positive results on cell free DNA screening: CVS or amnio? Prenat Diagn. 2021;41(10):1249-1254. https://doi.org/10.1002/pd.6021
van der Meij KRM, Sistermans EA, Macville MVE, et al. TRIDENT-2: National implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in The Netherlands. Am J Hum Genet. 2019;105(6):1091-1101. https://doi.org/10.1016/j.ajhg.2019.10.005
Van Den Bogaert K, Lannoo L, Brison N, et al. Outcome of publicly funded nationwide first-tier noninvasive prenatal screening. Genet Med. 2021;23(6):1137-1142. https://doi.org/10.1038/s41436-021-01101-4
van Prooyen Schuurman L, Sistermans EA, Van Opstal D, et al. Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: follow-up results of the TRIDENT-2 study. Am J Hum Genet. 2022;109(7):1344-1152. https://doi.org/10.1016/j.ajhg.2022.04.018
Benn P. Prenatal diagnosis of chromosomal abnormalities through chorionic villus sampling and amniocentesis. In: Milunsky A, Milunsky JM, eds. Genetic disorders of the fetus: diagnosis, prevention, and treatments. 8th ed. John Wiley & Sons, Inc.; 2021:404-498.
Benn P, Malvestiti F, Grimi B, Maggi F, Simoni G, Grati FR. Rare autosomal trisomies: comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples. Ultrasound Obstet Gynecol. 2019;54(4):458-467. https://doi.org/10.1002/uog.20383
Benn P, Grati FR, Ferreira J. Response to Sistermans et al. Genet Med. 2020;22(3):659-660. https://doi.org/10.1038/s41436-019-0687-7
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC).
de Wergifosse S, Bevilacqua E, Mezela I, et al. Cell-free DNA analysis in maternal blood: comparing genome-wide versus targeted approach as a first-line screening test. J Matern Fetal Neonatal Med. 2019:1-10.
Di Renzo GC, Bartha JL, Bilardo CM. Expanding the indications for cell-free DNA in the maternal circulation: clinical considerations and implications. Am J Obstet Gynecol. 2019;220(6):537-542. https://doi.org/10.1016/j.ajog.2019.01.009
Jani JC, Gil MM, Benachi A, et al. Genome-wide cfDNA testing of maternal blood. Ultrasound Obstet Gynecol. 2020;55(1):13-14. https://doi.org/10.1002/uog.21945
Benn P, Plon SE, Bianchi DW. Current controversies in prenatal diagnosis 2: NIPT results suggesting maternal cancer should always be disclosed. Prenat Diagn. 2019;39(5):339-343. https://doi.org/10.1002/pd.5379
Dhamankar R, DiNonno W, Martin KA, Demko ZP, Gomez-Lobo V. Fetal sex results of noninvasive prenatal testing and differences with ultrasonography. Obstet Gynecol. 2020;135(5):1198-1206. https://doi.org/10.1097/aog.0000000000003791
Wang Y, Chen Y, Tian F, et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem. 2014;60(1):251-259. https://doi.org/10.1373/clinchem.2013.215145
Martin KA, Samango-Sprouse CA, Kantor V, et al. Detection of maternal X chromosome abnormalities using single nucleotide polymorphism-based noninvasive prenatal testing. Am J Obstet Gynecol MFM. 2020;2(3):100152. https://doi.org/10.1016/j.ajogmf.2020.100152
Guidelines DNA-based non-invasive prenatal testing (non invasive prenatal testing - NIPT). Ministry of Health higher Health Council Section I. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2381_allegato.pdf
Cell-free DNA-based non-invasive prenatal testing (non invasive prenatal testing - NIPT) in healthcare system. Ministry of Health higher Health Council Section I. https://www.salute.gov.it/imgs/C_17_pubblicazioni_3097_allegato.pdf